ERBB2 and breast carcinoma: These results indicate that oleocanthal, as a c-Met inhibitor, could represent a safe and effective adjuvant agent in anticancer combination therapies aimed to selectively sensitize HER2-overexpressing breast cancer cells (without affecting the proliferation of non-cancerous cells), enhance the activity of HER2-targeted therapies (like lapatinib) and consequently reduce the required doses and toxicity of such therapies, as well as the possible emergence of HER2-targeted therapy resistance.